Doximity (DOCS) Stock Forecast, Price Target & Predictions
DOCS Stock Forecast
Doximity stock forecast is as follows: an average price target of $39.29 (represents a -6.05% downside from DOCS’s last price of $41.82) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
DOCS Price Target
The average price target for Doximity (DOCS) is $39.29 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $25.00. This represents a potential -6.05% downside from DOCS's last price of $41.82.
DOCS Analyst Ratings
According to 7 Wall Street analysts, Doximity's rating consensus is 'Buy'. The analyst rating breakdown for DOCS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 1 'Hold' (14.29%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Doximity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | Stephanie Davis | Barclays | $52.00 | $41.96 | 23.93% | 24.34% |
| Oct 08, 2024 | Elizabeth Anderson | Evercore ISI | $45.00 | $43.22 | 4.12% | 7.60% |
| Oct 07, 2024 | Allen Lutz | Bank of America Securities | $45.00 | $43.83 | 2.67% | 7.60% |
| Aug 09, 2024 | Scott Berg | Needham | $38.00 | $25.66 | 48.09% | -9.13% |
| May 17, 2024 | Stephanie Davis | Barclays | $31.00 | $27.89 | 11.15% | -25.87% |
| May 17, 2024 | Jailendra Singh | Truist Financial | $31.00 | $23.74 | 30.58% | -25.87% |
| May 17, 2024 | Elizabeth Anderson | Evercore ISI | $29.00 | $23.74 | 22.16% | -30.66% |
| Apr 23, 2024 | Craig Hettenbach | Morgan Stanley | $25.00 | $25.01 | -0.04% | -40.22% |
| Apr 01, 2024 | Elizabeth Anderson | Evercore ISI | $30.00 | $26.41 | 13.59% | -28.26% |
| Oct 23, 2022 | Elizabeth Anderson | Evercore ISI | $28.00 | $25.02 | 11.91% | -33.05% |
The latest Doximity stock forecast, released on Oct 15, 2024 by Stephanie Davis from Barclays, set a price target of $52.00, which represents a 23.93% increase from the stock price at the time of the forecast ($41.96), and a 24.34% increase from DOCS last price ($41.82).
Doximity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 4 | 9 |
| Avg Price Target | $47.33 | $45.00 | $36.22 |
| Last Closing Price | $41.82 | $41.82 | $41.82 |
| Upside/Downside | 13.18% | 7.60% | -13.39% |
In the current month, the average price target of Doximity stock is $47.33, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 13.18% increase as opposed to Doximity's last price of $41.82. This month's average price target is up 5.18% compared to last quarter, and up 30.67% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | Barclays | Equal-Weight | Overweight | Upgrade |
| Oct 08, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 20, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 09, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Aug 09, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 18, 2024 | Evercore ISI | Underperform | Underperform | Hold |
| Jul 18, 2024 | Wells Fargo | Neutral | Neutral | Hold |
| Jul 18, 2024 | Wells Fargo | Market Perform | Underweight | Downgrade |
| May 17, 2024 | Evercore ISI | Perform | Perform | Hold |
| Apr 23, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
Doximity's last stock rating was published by Barclays on Oct 15, 2024. The company Upgrade its DOCS rating from "Equal-Weight" to "Overweight".
Doximity Financial Forecast
Doximity Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $135.28M | $113.61M | $108.47M | $110.97M | $115.26M | $102.19M | $90.64M | $93.65M | $97.88M | $79.35M | $72.67M |
| Avg Forecast | $146.93M | $162.50M | $149.24M | $147.50M | $137.22M | $153.02M | $137.28M | $135.87M | $125.93M | $140.52M | $127.13M | $119.88M | $116.41M | $127.50M | $109.05M | $107.00M | $110.09M | $111.28M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| High Forecast | $146.93M | $162.50M | $149.24M | $147.50M | $137.22M | $153.02M | $137.28M | $135.87M | $125.93M | $140.52M | $127.48M | $119.88M | $116.41M | $128.11M | $109.66M | $107.00M | $110.09M | $111.28M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| Low Forecast | $146.93M | $162.50M | $149.24M | $147.50M | $137.22M | $153.02M | $137.28M | $135.87M | $125.93M | $140.52M | $126.98M | $119.88M | $116.41M | $127.10M | $108.56M | $107.00M | $110.09M | $111.28M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.01% | 1.01% | 1.04% | 1.02% | 1.01% | 1.04% | 1.13% | 1.08% | 1.14% |
Doximity's average Quarter revenue forecast for Mar 24 based on 4 analysts is $116.41M, with a low forecast of $116.41M, and a high forecast of $116.41M. DOCS's average Quarter revenue forecast represents a -13.95% decrease compared to the company's last Quarter revenue of $135.28M (Dec 23).
Doximity EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $58.55M | $33.79M | $32.29M | $35.55M | $41.10M | $34.69M | $24.05M | $29.29M | $37.17M | $26.53M | $26.07M |
| Avg Forecast | $44.81M | $49.56M | $45.52M | $44.99M | $41.85M | $46.67M | $41.87M | $41.44M | $38.41M | $42.86M | $38.77M | $36.56M | $21.25M | $38.88M | $33.26M | $32.63M | $19.32M | $26.99M | $30.55M | $27.33M | $17.56M | $26.31M | $22.41M | $24.05M |
| High Forecast | $44.81M | $49.56M | $45.52M | $44.99M | $41.85M | $46.67M | $41.87M | $41.44M | $38.41M | $42.86M | $38.88M | $36.56M | $25.50M | $39.07M | $33.45M | $32.63M | $23.18M | $32.38M | $30.55M | $27.33M | $21.08M | $26.31M | $22.41M | $28.86M |
| Low Forecast | $44.81M | $49.56M | $45.52M | $44.99M | $41.85M | $46.67M | $41.87M | $41.44M | $38.41M | $42.86M | $38.73M | $36.56M | $17.00M | $38.76M | $33.11M | $32.63M | $15.46M | $21.59M | $30.55M | $27.33M | $14.05M | $26.31M | $22.41M | $19.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51% | 1.02% | 0.99% | 1.84% | 1.52% | 1.14% | 0.88% | 1.67% | 1.41% | 1.18% | 1.08% |
4 analysts predict DOCS's average Quarter EBITDA for Mar 24 to be $21.25M, with a high of $25.50M and a low of $17.00M. This is -63.70% lower than Doximity's previous annual EBITDA (Dec 23) of $58.55M.
Doximity Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $47.96M | $30.60M | $28.41M | $30.67M | $33.47M | $26.30M | $22.38M | $36.73M | $55.65M | $36.09M | $26.32M |
| Avg Forecast | - | - | - | - | $52.65M | $62.34M | $52.87M | $52.51M | $47.06M | $55.52M | $50.82M | $44.46M | $26.66M | $47.48M | $33.41M | $28.47M | $24.24M | $40.40M | $29.99M | $19.95M | $22.04M | $22.21M | $17.34M | $24.28M |
| High Forecast | - | - | - | - | $52.65M | $62.34M | $52.87M | $52.51M | $47.06M | $55.52M | $52.77M | $44.48M | $32.00M | $49.46M | $37.12M | $28.47M | $29.09M | $48.48M | $29.99M | $19.95M | $26.44M | $22.21M | $17.34M | $29.14M |
| Low Forecast | - | - | - | - | $52.65M | $62.34M | $52.87M | $52.51M | $47.06M | $55.52M | $46.91M | $44.44M | $21.33M | $43.52M | $29.70M | $28.47M | $19.39M | $32.32M | $29.99M | $19.95M | $17.63M | $22.21M | $17.34M | $19.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.92% | 1.00% | 1.27% | 0.83% | 0.88% | 1.12% | 1.67% | 2.51% | 2.08% | 1.08% |
Doximity's average Quarter net income forecast for Mar 24 is $26.66M, with a range of $21.33M to $32.00M. DOCS's average Quarter net income forecast represents a -44.40% decrease compared to the company's last Quarter net income of $47.96M (Dec 23).
Doximity SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $44.60M | $39.17M | $43.70M | $42.91M | $42.73M | $37.77M | $36.86M | $36.54M | $34.78M | $29.99M | $26.57M |
| Avg Forecast | $55.73M | $61.64M | $56.61M | $55.95M | $52.05M | $58.05M | $52.07M | $51.54M | $47.77M | $53.30M | $48.23M | $45.48M | $26.53M | $48.36M | $41.37M | $40.59M | $24.12M | $25.25M | $37.99M | $33.99M | $21.93M | $32.72M | $27.88M | $24.51M |
| High Forecast | $55.73M | $61.64M | $56.61M | $55.95M | $52.05M | $58.05M | $52.07M | $51.54M | $47.77M | $53.30M | $48.36M | $45.48M | $31.84M | $48.60M | $41.60M | $40.59M | $28.94M | $30.30M | $37.99M | $33.99M | $26.31M | $32.72M | $27.88M | $29.41M |
| Low Forecast | $55.73M | $61.64M | $56.61M | $55.95M | $52.05M | $58.05M | $52.07M | $51.54M | $47.77M | $53.30M | $48.17M | $45.48M | $21.22M | $48.21M | $41.18M | $40.59M | $19.29M | $20.20M | $37.99M | $33.99M | $17.54M | $32.72M | $27.88M | $19.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.95% | 1.08% | 1.78% | 1.69% | 0.99% | 1.08% | 1.67% | 1.06% | 1.08% | 1.08% |
Doximity's average Quarter SG&A projection for Mar 24 is $26.53M, based on 4 Wall Street analysts, with a range of $21.22M to $31.84M. The forecast indicates a -40.51% fall compared to DOCS last annual SG&A of $44.60M (Dec 23).
Doximity EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.26 | $0.16 | $0.15 | $0.16 | $0.17 | $0.14 | $0.12 | $0.19 | $0.30 | $0.19 | $0.30 |
| Avg Forecast | - | - | - | - | $0.26 | $0.31 | $0.27 | $0.26 | $0.24 | $0.28 | $0.26 | $0.22 | $0.20 | $0.24 | $0.17 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| High Forecast | - | - | - | - | $0.26 | $0.31 | $0.27 | $0.26 | $0.24 | $0.28 | $0.26 | $0.22 | $0.20 | $0.25 | $0.19 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| Low Forecast | - | - | - | - | $0.26 | $0.31 | $0.27 | $0.26 | $0.24 | $0.28 | $0.24 | $0.22 | $0.20 | $0.22 | $0.15 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.95% | 1.05% | 0.93% | 0.97% | 0.93% | 1.20% | 1.29% | 2.69% | 2.18% | 4.71% |
According to 4 Wall Street analysts, Doximity's projected average Quarter EPS for Mar 24 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a -22.82% decrease compared to DOCS previous annual EPS of $0.26 (Dec 23).
Doximity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TDOC | Teladoc Health | $8.87 | $50.87 | 473.51% | Hold |
| ACCD | Accolade | $3.15 | $14.81 | 370.16% | Buy |
| DH | Definitive Healthcare | $4.08 | $9.50 | 132.84% | Hold |
| CERT | Certara | $10.25 | $20.60 | 100.98% | Buy |
| PGNY | Progyny | $15.15 | $29.00 | 91.42% | Hold |
| TXG | 10x Genomics | $16.78 | $30.20 | 79.98% | Hold |
| SDGR | Schrödinger | $18.24 | $28.67 | 57.18% | Buy |
| HQY | HealthEquity | $86.95 | $97.00 | 11.56% | Buy |
| VEEV | Veeva Systems | $212.53 | $229.71 | 8.08% | Buy |
| GEHC | GE HealthCare | $86.99 | $93.40 | 7.37% | Buy |
| DOCS | Doximity | $41.82 | $39.29 | -6.05% | Buy |
| AMWL | American Well | $9.12 | $8.40 | -7.89% | Hold |
DOCS Forecast FAQ
Is Doximity a good buy?
Yes, according to 7 Wall Street analysts, Doximity (DOCS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of DOCS's total ratings.
What is DOCS's price target?
Doximity (DOCS) average price target is $39.29 with a range of $25 to $52, implying a -6.05% from its last price of $41.82. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Doximity stock go up soon?
According to Wall Street analysts' prediction for DOCS stock, the company can go down by -6.05% (from the last price of $41.82 to the average price target of $39.29), up by 24.34% based on the highest stock price target, and down by -40.22% based on the lowest stock price target.
Can Doximity stock reach $60?
DOCS's average twelve months analyst stock price target of $39.29 does not support the claim that Doximity can reach $60 in the near future.
What is Doximity's current price target trend?
3 Wall Street analysts forecast a $47.33 price target for Doximity (DOCS) this month, up 13.18% from its last price of $41.82. Compared to the last 3 and 12 months, the average price target increased by 7.60% and decreased by -13.39%, respectively.
What are Doximity's analysts' financial forecasts?
Doximity's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $563.38M (high $563.38M, low $563.38M), average EBITDA is $171.82M (high $171.82M, low $171.82M), average net income is $220.37M (high $220.37M, low $220.37M), average SG&A $213.71M (high $213.71M, low $213.71M), and average EPS is $1.11 (high $1.11, low $1.11). DOCS's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $606.17M (high $606.17M, low $606.17M), average EBITDA is $184.87M (high $184.87M, low $184.87M), average net income is $0 (high $0, low $0), average SG&A $229.94M (high $229.94M, low $229.94M), and average EPS is $0 (high $0, low $0).
Did the DOCS's actual financial results beat the analysts' financial forecasts?
Based on Doximity's last annual report (Mar 2023), the company's revenue was $419.05M, beating the average analysts forecast of $411.14M by 1.92%. Apple's EBITDA was $135.39M, beating the average prediction of $104.18M by 29.96%. The company's net income was $112.82M, missing the average estimation of $114.58M by -1.53%. Apple's SG&A was $160.27M, beating the average forecast of $121.35M by 32.07%. Lastly, the company's EPS was $0.58, missing the average prediction of $0.599 by -3.13%. In terms of the last quarterly report (Dec 2023), Doximity's revenue was $135.28M, beating the average analysts' forecast of $127.5M by 6.11%. The company's EBITDA was $58.55M, beating the average prediction of $38.88M by 50.58%. Doximity's net income was $47.96M, beating the average estimation of $47.48M by 1.00%. The company's SG&A was $44.6M, missing the average forecast of $48.36M by -7.79%. Lastly, the company's EPS was $0.26, beating the average prediction of $0.238 by 9.09%